Organon & Co. (NYSE:OGN) Reaches New 52-Week High – Should You Buy?

Shares of Organon & Co. (NYSE:OGN) reached a new 52-week high during trading on Tuesday. The stock traded as high as $13.89 and last traded at $13.8850, with a volume of 1,337,922 shares changing hands. The stock had previously closed at $13.85.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Organon & Co. presently has an average rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Trading Up 0.3%

The firm has a market capitalization of $3.65 billion, a PE ratio of 18.28, a P/E/G ratio of 1.27 and a beta of 1.53. The company has a quick ratio of 1.44, a current ratio of 2.02 and a debt-to-equity ratio of 7.11. The business’s fifty day moving average price is $13.75 and its 200 day moving average price is $11.62.

Organon & Co. (NYSE:OGN) last announced its earnings results on Friday, October 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.06. The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.58 billion. Organon & Co. had a net margin of 3.49% and a return on equity of 82.06%. As a group, analysts expect that Organon & Co. will post 3.24 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Monday, November 9th will be issued a dividend of $0.02 per share. The ex-dividend date is Monday, November 9th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is 10.53%.

Institutional Trading of Organon & Co.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Voya Investment Management LLC increased its position in Organon & Co. by 1.5% during the 3rd quarter. Voya Investment Management LLC now owns 81,254 shares of the company’s stock worth $1,113,000 after purchasing an additional 1,232 shares in the last quarter. HighTower Advisors LLC lifted its position in Organon & Co. by 3.9% during the third quarter. HighTower Advisors LLC now owns 48,346 shares of the company’s stock valued at $662,000 after buying an additional 1,797 shares in the last quarter. Alberta Investment Management Corp lifted its position in Organon & Co. by 22.2% during the third quarter. Alberta Investment Management Corp now owns 550,000 shares of the company’s stock valued at $7,535,000 after buying an additional 100,000 shares in the last quarter. First Trust Capital Management L.P. lifted its position in Organon & Co. by 2.8% during the third quarter. First Trust Capital Management L.P. now owns 402,040 shares of the company’s stock valued at $5,508,000 after buying an additional 11,101 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Organon & Co. by 3.7% during the third quarter. Russell Investments Group Ltd. now owns 114,092 shares of the company’s stock worth $1,563,000 after buying an additional 4,071 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co. is a global health care company focused on women’s health, biosimilars and established medicines. It develops and markets prescription medicines and other health products for patients and health care professionals. Its women’s health portfolio includes contraceptive and fertility products, while its biosimilars business offers biologic medicines in areas such as immunology and oncology. The company also sells established medicines across several therapeutic areas, including cardiovascular health, respiratory conditions and dermatology.